Literature DB >> 25663972

Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis.

Xueren Li1, Shouchun Peng1, Luqing Wei1, Zhenhua Li2.   

Abstract

OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia with unknown cause. We analyzed the changed rate of pulmonary function and arterial blood gas in IPF patients, and evaluated their influence of changed rate to IPF prognosis.
METHODS: 81 patients with IPF were recruited successfully, they were followed-up at 6 and 12 months. Dyspnea score and respiratory assessment parameters including FVC, FEV1, TLC, SaO2, PA-aO2, and DLCO were evaluated at their 6 and 12 months follow-up. The changed value and changed rate of above parameters were calculated, and their treatment effects were divided into 3 subgroup: improved, stable and deteriorated group. Statistical analysis was performed between groups for survival and hazards regression analysis.
RESULTS: 55 of 81 patients were follow-up at 12 months. Dyspnea score and its changed rate, the changed value of FEV1%, FVC%, TLC%, DLCO%, and PaO2, SaO2, PA-aO2 were prognosis effect factors in IPF patients in 6 and 12 months group. The survival analysis of dyspnea scores, FVC%, TLC%, DLCO%, PaO2, SaO2 and PA-aO2 at K-M were all statistical significant (P < 0.05) in improved, stable and deteriorated group.
CONCLUSION: FVC% changed rate, dyspnea score changed rate and PaO2 changed rate were IPF patient prognosis associated factors in 6 months group; and FVC% changed rate, DLCO% changed rate and TLC% changed rate were prognosis associated factors for IPF patient in 12 months group.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; prognosis; respiratory assessment parameters; survival analysis

Year:  2014        PMID: 25663972      PMCID: PMC4307419     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  29 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation.

Authors:  N Mogulkoc; M H Brutsche; P W Bishop; S M Greaves; A W Horrocks; J J Egan
Journal:  Am J Respir Crit Care Med       Date:  2001-07-01       Impact factor: 21.405

3.  Familial idiopathic interstitial pneumonia: histopathology and survival in 30 patients.

Authors:  Kevin O Leslie; Carlyne D Cool; Thomas A Sporn; Douglas Curran-Everett; Mark P Steele; Kevin K Brown; Momen M Wahidi; David A Schwartz
Journal:  Arch Pathol Lab Med       Date:  2012-11       Impact factor: 5.534

4.  Prognosis of cryptogenic fibrosing alveolitis.

Authors:  P Tukiainen; E Taskinen; P Holsti; O Korhola; M Valle
Journal:  Thorax       Date:  1983-05       Impact factor: 9.139

5.  The prognostic significance of functional tests in cryptogenic fibrosing alveolitis.

Authors:  V Jezek; J Fucik; A Michaljanic; L Jezkova
Journal:  Bull Eur Physiopathol Respir       Date:  1980 Nov-Dec

6.  The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

Authors:  A G Nicholson; T V Colby; R M du Bois; D M Hansell; A U Wells
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

7.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.

Authors:  D W Mapel; W C Hunt; R Utton; K B Baumgartner; J M Samet; D B Coultas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

8.  Determinants of progression in idiopathic pulmonary fibrosis.

Authors:  D A Schwartz; D S Van Fossen; C S Davis; R A Helmers; C S Dayton; L F Burmeister; G W Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  1994-02       Impact factor: 21.405

9.  Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group.

Authors:  W W Douglas; J H Ryu; S J Swensen; K P Offord; D R Schroeder; G M Caron; R A DeRemee
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

10.  A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391

View more
  3 in total

Review 1.  Pulmonary Function Changes After Radiotherapy for Lung or Esophageal Cancer: A Systematic Review Focusing on Dose-Volume Parameters.

Authors:  Anne G H Niezink; Renske A de Jong; Christina T Muijs; Johannes A Langendijk; Joachim Widder
Journal:  Oncologist       Date:  2017-05-26

2.  Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease.

Authors:  Yiliang Su; Hongyan Gu; Dong Weng; Ying Zhou; Qiuhong Li; Fen Zhang; Yuan Zhang; Li Shen; Yang Hu; Huiping Li
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

Review 3.  Shared decision making in peri-operative medicine: Miles to go in Indian scenario.

Authors:  G V Krishna Prasad
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2020-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.